Type 2 diabetes is a common condition managed in primary care. Although clinical practice guidelines recommend specific targets for blood pressure, LDL-C and A1C, primary care research has demonstrated only a small portion of patients with type 2 diabetes are meeting these targets. With the Diabetes Canada 2020 guideline update, clinicians are still encouraged to meet glycemic targets, but there is an increased focus on selecting antihyperglycemic agents that can improve outcomes in patients with diabetes. This module will focus on providing recommendations on the intensification of antihyperglycemic therapy beyond metformin in people with type 2 diabetes.
This program has received an unrestricted educational grant or in-kind support from Novo Nordisk A/S.